Chondroitin sulfate (Honsat) injections 100 mg/ml 2 ml – [10 ampoules]

A high-molecular-weight mucopolysaccharide that affects metabolic processes in hyaline cartilage. The drug has chondroprotective, stimulating the regeneration of cartilage tissue, anti-inflammatory effect. Participates in the construction of the basic substance of cartilage and bone tissue, improves phosphorus-calcium metabolism in the cartilage tissue, inhibits enzymes that disrupt the structure and function of articular cartilage, inhibits the process of degeneration of cartilage. Stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, promotes the regeneration of cartilage surfaces and the joint capsule. It prevents compression of the connective tissue, increases synovial fluid production and mobility of affected joints, reduces associated inflammation and pain, and helps reduce the need for NSAIDs. In degenerative changes of cartilage tissue is a means of substitution therapy.

Positive effect is observed 2-3 weeks after the start of drug administration: joint pain decreases, clinical manifestations of reactive synovitis disappear, the volume of movements in the affected joints increases. The therapeutic effect lasts for a long time (3-6 months) after the end of treatment.

Degenerative-dystrophic diseases of the joints and spine:

– osteoarthritis of the peripheral joints;

– Intervertebral osteochondrosis and osteoarthritis.

To accelerate the formation of the bone callus at fractures.

– Hypersensitivity to Chondroitin sulfate (Honsat) or its components.

– Bleeding and a tendency to bleeding, thrombophlebitis.

– Childhood age.

– Pregnancy and lactation.

Administration during pregnancy and lactation

At this time there is no known data on the use of Chondroitin sulfate (Honsat) during pregnancy and breastfeeding.